Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Molecular Partners
Biotech
Molecular Partners tweaks AML trial over 'suboptimal exposure'
The biotech identified “suboptimal exposure” to its tetra-specific T-cell engager as the cause of the limited response rate in its early-phase trial.
Nick Paul Taylor
Aug 27, 2024 10:00am
Amgen opts to DARP-out after seeing Molecular Partners data
Apr 26, 2022 4:38pm
Novartis splashes cash on COVID-19 antiviral, plans FDA filing
Jan 10, 2022 4:48am
JPM22, Day 1: Bayer strikes a Mammoth deal and more
Jan 10, 2022 4:25am
Novartis tags Molecular Partners for $580M radioligand deal
Dec 14, 2021 10:34am
Novartis-partnered DARPin flames out in COVID-19 study
Nov 16, 2021 8:15am
